Is it possible to cure the symptoms of the overactive bladder in women?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901Z0A" target="_blank" >RIV/61988987:17110/18:A1901Z0A - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/18:10376595 RIV/00843989:_____/18:E0107022 RIV/00064190:_____/18:N0000030 RIV/00064165:_____/18:10376595

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s11255-017-1777-6" target="_blank" >http://dx.doi.org/10.1007/s11255-017-1777-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11255-017-1777-6" target="_blank" >10.1007/s11255-017-1777-6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Is it possible to cure the symptoms of the overactive bladder in women?

Popis výsledku v původním jazyce

To evaluate the feasibility of discontinuing treatment with mirabegron once symptoms have subsided in patients with overactive bladder (OAB). The present study evaluated a total of 159 female OAB patients (age 62.9 +/- 12.36), each of which were prescribed 50 mg/day mirabegron (Time point 1-T1). Data obtained from voiding diaries and patient-reported outcome variables were assessed during follow-up visits at months 1, 3, 6, 12, 18 (T2), and 21 (T4). At the 18-month visit, patients with an Urgency Bother-Visual Analog Scale score of ae&lt;currency&gt; 50% were advised to stop treatment with mirabegron. Upon re-emergence or worsening of OAB symptoms, patients were allowed to start taking medication again at their discretion (T3). Statistical analysis was performed using a Chi-square test. An ANOVA analysis and a two-sample t test were used to evaluate differences between groups. A total of 56 out of 159 (35.3%) patients took 50 mg of mirabegron daily between T1 and T2. A total of 17 out of 56 patients (30.4%) did not meet the criteria for mirabegron discontinuation (Group A). A total of 24 out of 56 patients (42.9%) stopped taking the medication temporarily, but later returned to treatment (Group B). The average time span between T2 and T3 was 53.9 days. Fifteen of 56 patients (26.8%) ceased treatment with mirabegron without starting it again before T4 (Group C). The average time span between T2 and T4, in Group C, was 124.7 days. A small percentage of OAB patients were able to discontinue mirabegron due to symptom cessation.

Název v anglickém jazyce

Is it possible to cure the symptoms of the overactive bladder in women?

Popis výsledku anglicky

To evaluate the feasibility of discontinuing treatment with mirabegron once symptoms have subsided in patients with overactive bladder (OAB). The present study evaluated a total of 159 female OAB patients (age 62.9 +/- 12.36), each of which were prescribed 50 mg/day mirabegron (Time point 1-T1). Data obtained from voiding diaries and patient-reported outcome variables were assessed during follow-up visits at months 1, 3, 6, 12, 18 (T2), and 21 (T4). At the 18-month visit, patients with an Urgency Bother-Visual Analog Scale score of ae&lt;currency&gt; 50% were advised to stop treatment with mirabegron. Upon re-emergence or worsening of OAB symptoms, patients were allowed to start taking medication again at their discretion (T3). Statistical analysis was performed using a Chi-square test. An ANOVA analysis and a two-sample t test were used to evaluate differences between groups. A total of 56 out of 159 (35.3%) patients took 50 mg of mirabegron daily between T1 and T2. A total of 17 out of 56 patients (30.4%) did not meet the criteria for mirabegron discontinuation (Group A). A total of 24 out of 56 patients (42.9%) stopped taking the medication temporarily, but later returned to treatment (Group B). The average time span between T2 and T3 was 53.9 days. Fifteen of 56 patients (26.8%) ceased treatment with mirabegron without starting it again before T4 (Group C). The average time span between T2 and T4, in Group C, was 124.7 days. A small percentage of OAB patients were able to discontinue mirabegron due to symptom cessation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

INTERNATIONAL UROLOGY AND NEPHROLOGY

ISSN

0301-1623

e-ISSN

—

Svazek periodika

3

Číslo periodika v rámci svazku

50

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

7

Strana od-do

433-439

Kód UT WoS článku

000427128300007

EID výsledku v databázi Scopus

2-s2.0-85040341954